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Summary A phase trial of the combination of irinotecan (CPT-11) with cisplatin in advanced non-small cell lung cancer (NSCLC) showed a
very promising response rate of 54% in previously untreated NSCLC patients. This study was conducted to confirm the activity and toxicities
of CPT-11 and cisplatin combination for previously untreated NSCLC in a multi-institutional phase 11 study. Seventy patients with stage IIIB or
IV NSCLC received CPT-11 60 mg m-2 intravenously (IV) on days 1, 8 and 15, and cisplatin 80 mg m-2 (IV) on day 1 every 4 weeks.
Assessments were made of response, survival and toxicities. Sixty-nine were eligible, and evaluable for toxicities and survival, and 64
patients evaluable for response. Thirty-three patients (52%; 95% confidence interval 39-64%) achieved an objective response, with one
complete response (2%) and 32 partial responses (50%). The median duration of response was 19 weeks and the overall median survival
time was 44 weeks. The 1-year survival rate was 33%. The major toxic effects were leucopenia and diarrhoea. Grade 3 or 4 leucopenia,
neutropenia, and diarrhoea occurred in 32 patients (46%), 53 patients (80%), and 13 patients (19%) respectively. A combination of CPT-11
and cisplatin is very effective against non-small-cell lung cancer with acceptable toxicities.
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Lung cancer is a major health care problem throughout the world.
Non-small-cell lung cancer (NSCLC) accounts for approximately
75% of all lung cancers. Only a small proportion of patients will
be cured by surgery, and most will have metastatic disease and
require systemic treatment. Unfortunately, NSCLC is in the group
ofneoplastic diseases that are relatively chemoresistant. Although
a modest survival benefit was noted by meta-analysis (Grilli et al,
1993; Souquet et al, 1993), no regimen is completely effective and
none has led conclusively to a cure, and there is no standard
chemotherapy programme for this disease (Ginsberg et al, 1993).
Therefore, it is imperative to develop combination regimens of
new active compounds with novel mechanisms of actions.
Irinotecan (CPT-11) is a water-soluble camptothecin derivative
that targets DNA topoisomerase I. CPT- 11 has shown a strong
anti-tumour activity as a single agent against a broad spectrum of
experimental tumours (Kunimoto et al, 1987; Matsuzaki et al,
1988) as well as against various human malignancies including
lung cancer (Ohno et al, 1990; Negoro et al, 1991b; Tacheuchi
et al, 1991; Fukuoka et al, 1992; Masuda et al, 1992a; Shimada
et al, 1993).
The response rate of32% to CPT-11 for NSCLC is very encour-
aging (Fukuoka et al, 1992). Both CPT-11 and cisplatin are active
against NSCLC. Because of the differences in mechanisms of
action (Andoh et al, 1987; Zwelling and Kohn, 1979) and toxicity
profiles (Gottlieb and Drewinko, 1975; Negoro et al, 1991a), and
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with limited cross-resistance (Tsuruo et al, 1988; Noda et al, 1991;
Masuda et al, 1992a) between the two drugs, the synergism
between CPT-11 and its major active metabolite, 7-ethyl-10-
hydroxycamptothecin (SN-38) in combination with cisplatin
(Kudoh et al, 1993) seems to have enormous clinical potential.
Based on these reports, we conducted a phase I trial of the combi-
nation of CPT-11 (escalating doses) with cisplatin in advanced
NSCLC (Masuda et al, 1992b). A response rate of 54% in previ-
ously untreated NSCLC patients was very encouraging, even
although some patients received relatively low doses of CPT-11.
The results of the pilot study led to the multi-institutional phase II
study reported here, which was designed to determine the anti-
tumour activity and toxicities of a combination of CPT-11 and
cisplatin in previously untreated patients with advanced NSCLC.
PATIENTS AND METHODS
Patient selection
Before participation in the study, each patient was examined to
make sure he or she met the following criteria: (a) histological
diagnosis of non-small-cell lung cancer; (b) stage IIIB or IV
disease; (c) no prior chemotherapy or radiotherapy; (d) life
expectancy of at least 8 weeks; (e) age < 75 years; (f) performance
status of 2 or better on the Eastern Cooperative Oncology Group
(ECOG) scale; (g) adequate bone marrow function (leucocyte
count .4000 l1-', platelet count 2 100 000,l- and haemoglobin
concentration 2 9 g dl-'), hepatic function (bilirubin < 1.5 mg dl-,
transaminases < 2 x upper limit of normal), and renal function
(creatinine < upper limit of normal, creatinine clearance
2 60 ml min-1); (h) free ofany concurrent active malignancy; (i) no
medical problems sufficiently severe to prevent compliance with
the study requirements; and (j) written informed consent of the
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Table 1 Characteristics of eligible patients



























patient. Patients were not eligible ifthey showed allergic reactions to
skin-prick test with CPT-11. Pregnant women were also ineligible.
Treatment plan
CPT- 11 at a dose of 60 mg m-2 was given in 500 ml of normal
saline as a 90 min intravenous infusion on days 1, 8 and 15 every 4
weeks. CPT-11 was provided by Daiichi Pharmaceutical, Tokyo,
Japan, and Yakult Honsha, Tokyo, Japan. A 80 mg m-2 sample of
cisplatin was given on day 1 after the CPT- 11 administration every
4 weeks. These doses were the recommended doses of a combina-
tion ofCPT-11 and cisplatin in a previous phase I/II study (Masuda
et al, 1992b). During the course of the treatment, the dose of
CPT- 1I was withheld in instances of leucocyte count <3000 ,ul-,
platelet count <100 000,l-1 or grade >2 diarrhoea on the day
when the dose was due. Patients with obvious evidence of disease
progression or unmanageable toxicity were removed from the
study. Patients who were stabilized received at least a second
course of treatment; those with objective tumour response were
eligible to continue therapy for a maximum of six courses. Before
the next course was started, the WBC count had to be 4000 ul-' or
higher, the platelet count had to be 100 000 pl-I or higher, the
serum creatinine level had to be normal and diarrhoea should be
recovered completely.
Subsequent doses were modified on the basis of haematological
and non-haematological toxicities. If during the previous cycle
the leucocyte nadir was <2000 ,ul-' and/or the platelet nadir was
<50 000 ,l' or if the subsequent cycle was delayed for more than
2 weeks, the dose of CPT-11 was reduced to 50 mg m-2. The dose
of CPT-11 was also reduced to 50 mg m-2 in cases of diarrhoea
> grade 3. A prophylactic anti-diarrhoeal regimen was not used in
this trial. If the serum creatinine concentration was > 1.7 mg dl-',
or the creatinine clearance was below 60 ml min-', the cisplatin
dose was reduced to 60 mg m-2. Dose adjustments were also
made for other toxicities 2 grade 3, except for nausea and
vomiting, and alopecia.
Evaluation
Patients were evaluated to determine the stage of disease by
complete medical history and physical examination, routine chest
radiograph, whole-lung tomography, bone scintiscan, computer-
ized tomography of the head, chest and abdomen, and fibreoptic
bronchoscopy. The staging procedures were those of the
tumour-node-metastasis system (Mountain, 1986). Before the
first course, each patient was subject to a complete blood count
(CBC), including a differential count and a platelet count, and
serum chemistry was used to check renal and hepatic functions,
electrolytes and urinalysis. CBC, serum chemistry, electrolytes,
urinalysis, and chest radiographs were assessed at least once a
week after the initial evaluation. Other appropriate investigations
were repeated weekly to evaluate the sites of marker lesions. After
the completion of chemotherapy, each patient was restaged with
all the tests used during the initial work-up, except for the fibre-
optic bronchoscopy. The eligibility, evaluability and response of
each patient were assessed by extramural reviewers. The tumour
responses and toxicities, except diarrhoea, were classified in
accordance with the World Health Organization (WHO) criteria
Table 2 Response to a combination of CPT-11 and cisplatin treatment
Number of Response P-
patients CR PR NC PD NE rate (%) value
Overall 69 1 32 28 3 5 52*
Sex
Male 51 1 20 25 2 3 44 0.178
Female 18 0 12 3 1 2 75
Performance status (ECOG)
0-1 57 1 27 24 2 3 52 0.866
2 12 0 5 4 1 2 50
Stage
IIIB 26 1 10 12 0 3 48 0.116
IV 43 0 22 16 3 2 14
Histology
Adenocarcinoma 51 1 26 18 2 4 57 0.618
Squamous cell cancer 15 0 5 8 1 1 36
Large cell cancer 3 0 1 2 0 0 33
CR, complete response; PR, partial response; NC, no change; PD, progressive disease; NE, non-evaluable;* 95% confidence Interval, 39-64%
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Figure 1 Median survival times in all patients with advanced non-small cell
lung cancer were 44 weeks, 49 weeks/stage IIIB ( ), and 38 weeks/stage
IV disease (--- -) respectively (P= 0.1185; log-rank test). The 1-, 2- and 3-
year actuarial survival rates in patients with stage IIIB disease were 46.2%,
17.9%, and 9.0%, compared with 25.6%, 4.7%, and 4.7%, respectively, in the
patients with stage IV disease
(World Health Organization, 1979). ECOG common toxicity
criteria were used to grade diarrhoea. Patients were considered
evaluable if they had completed at least one treatment cycle. The
duration ofeach response was defined as the number ofdays from
the start of treatment to its progression. The duration of survival
was determined as the number of days from the start of treatment
to death or the last follow-up.
Statistical methods
The method of Kaplan and Meier (1958) was used to derive the
survival curve and response duration, and was compared using the
log-rank test. Other statistical analyses were performed using the
chi-squared test or Fisher's exact test, and P < 0.05 was considered
to indicate statistical significance. The primary end point was the
response rate, which determined sample size. The statistical focus
centred on distinguishing a response rate of 60% from the usual
expected response rate of 35% obtained with a combination of
cisplatin and vindesine in patients with advanced NSCLC. Our
design had a power in excess of80% and less than 5% type I error.
Assuming an inevaluability rate of less than 20%, we projected an
accrual of > 60 patients.
RESULTS
Between February 1992 and August 1992, 70 patients participated
in the trial. One patient was deemed ineligible because he had
stage IIIA disease. The characteristics ofthe eligible patient popu-
lation are listed in Table 1. Eighteen patients were women and 51
were men, and the median age was 61 years (range 37-75 years).
A total of 26 (38%) patients had stage IIIB disease and 43 (62%)
had stage IV disease.
Response and survival
Sixty-four patients were fully assessable for response. Of the five
non-assessable patients, two died of toxicity during the first cycle
of treatment, two received treatment only on day 1 because of
delayed recovery from leucopenia and paralytic ileus, respectively,
and one refused further protocol treatment after day I treatment
because of severe nausea and vomiting, loss of appetite and
general fatigue. Among the 64 assessable patients, one patient
achieved a complete response and 32 (50%) had a partial response
for an overall response rate of 52% (95% confidence interval,
39%-64%) (Table 2). The median time required to reach remission
was 27 days (range 7-63 days). Twenty-eight patients showed no
change and three had disease progression. The response rates for
adenocarcinoma, squamous cell carcinoma and large-cell carci-
noma were 57% (27 out of47 patients), 36% (5 out of 14 patients)
and 33% (one out ofthree patients) respectively (P = 0.618). There
was no significant difference in overall response rate when
analysed by sex, performance status (0-1 vs 2) (P = 0.866), or by
stage (stage IIIB vs stage IV) (P = 0.1 16). The median duration of
response for all responding patients was 19 weeks (range 8-52
weeks), and that for patients with stage IV disease was 20 weeks
(range 8-52 weeks). Of26 patients with stage IIIB disease, consol-
idation chest irradiation was used in five patients after reaching
a maximal response. An additional six patients with stage IIIB
received thoracic radiotherapy after confirming that their
responses showed no change.
Of the 69 patients, only two patients (3%) were still alive as of
13 November 1996. One patient was lost to follow-up 74 weeks
after the beginning of treatment. The median survival time for all
69 patients was 44 weeks (stage IIIB patients, 49 weeks; stage IV
patients, 38 weeks) (Figure 1). The 1-, 2- and 3-year actuarial
survival rates in patients with stage IIIB disease were 46.2%,
17.9%, and 9.0%, compared with 25.6%, 4.7% and 4.7%, respec-
tively, in the patients with stage IV disease. The 1-year survival
rate was 33.3%, with a 95% confidence interval of22-44%.
Toxicity
There were two treatment-related deaths on days 8 and 15 of
cycle I as a result of neutropenic sepsis coincidentally associated
with paralytic ileus. Another nine patients were taken off the study
after the first cycle of treatment because of progressive disease
(two), patient refusal (one), severe diarrhoea (two), paralytic ileus
(one), delayed recovery from leucopenia (one), pulmonary toxicity
(one) and skin rash (one). Fifty-eight patients received multiple
courses of treatment in successive cycles. A total of 175 courses
were given; all were valid for toxicity analysis (mean cycles per
patient, 2.5: range 1-6). Reduction of the cisplatin dose was
required in only two patients (three cycles). Details of the CPT- 11
dose actually delivered are listed in Table 3. Thirty-six (52%) of69
patients could receive CPT-11 treatment three times during cycle
1. Virtually all episodes of severe leucopenia and/or diarrhoea
were observed during cycle I as dose modifications were made in
subsequent cycles. Consequently, it was possible to deliver the full
doses of CPT- II treatment (three times) in 59% of the entire 175
cycles, suggesting little evidence of cumulative toxicity during the
subsequent courses of treatment. The reasons why patients could
not receive CPT- 1I treatment three times in the first course were
treatment-induced leucopenia (33%), thrombocytopenia (9%)
and/or diarrhoea (17%).
Table 4 shows the maximum toxicities experienced during the
treatment. The most frequent toxicity was myelosuppression, which
primarily affected leucocytes: grade 3 or 4 neutropenia occurred in
23'%/ and 9% of patients respectively. The leucocyte nadir usually
occurred around day 17, with recovery in most patients by day 29.
Little cumulative toxicity was detected in the subsequent courses. Of
66 patients, 28 (42%) developed grade 3 neutropenia (absolute
neutrophil count = 500 to 1000 gtl') and 25 (38%) had grade 4
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Table 3 Number of CPT-11 doses actually delivered to patients
During the first course During all courses
Number of patients (%) Numbers of courses (%)
(n = 69) (n = 175)
Full dose (days 1, 8,15) 36 (52) 104 (59)
Twice
(days 1, 8) 23 (33) 42 (24)
(days 1,15) 5 (7) 17 (10)
Only once (day 1) 5 (7) 12 (7)
Table 4 Toxicities of CPT-11/cisplatin combination chemotherapy
Toxicity (%) Number of patients WHO grade Number of
assessable > grade 3
1 2 3 4
Leucopenia 69 8 24 23 9 32 (46)
Neutropenia 66 1 8 28 25 53 (80)
Thrombocytopenia 69 11 2 2 4 6 (9)
Anaemia 68 15 19 20 4 24 (35)
Nausea/vomiting 69 18 21 24 - 24 (35)
Diarrhoea 69 26 16 10 3 13 (19)
Alopecia 69 21 30 5 - 5 (7)
Pulmonary toxicity 69 0 0 0 1 1 (1)
Ileus 69 0 0 0 3 3(4)
Fever 69 1 5 0 0 0 (0)
Elevation of serum creatinine 69 8 1 0 0 0 (0)
Elevation of transaminases 68 12 1 0 0 0 (0)
Mucositis 69 2 0 0 0 0 (0)
neutropenia (absolute neutrophil count <500 tl). Among 69
patients, 29 (42%) patients received granulocyte colony-stimulating
factor when they experienced leucopenia. Transient eosinophilia in
10% or more ofleucocytes was observed in 12 (18%) of67 patients.
Thrombocytopenia remained infrequent throughout the study: grade
3 and 4 toxicity only occurred in 3% and 6% ofthe patients respec-
tively. Thirty-five per cent ofpatients had grade 3 or 4 anaemia.
Non-haematological toxicities were also significant. Gastro-
intestinal toxicity was a prominent toxic effect of this treatment.
Grade 3 nausea and vomiting occurred in 24 (35%) patients. Grade
3 and 4 diarrhoea was observed in 10 (14%) and 3 (4%) patients.
Maximal grade diarrhoea occurred on a median of day 11 (range:
day 1-18), and recovery was observed in a median of 4 days
(range: 1-12 days). Although treatment ofdiarrhoea was left at the
discretion ofthe treating physicians, most ofthe patients with diar-
rhoea were treated with loperamide, as reported by Abigerges et al
(1994). However, three (4%) patients experienced grade 4 para-
lytic ileus, two of whom died early in the treatment as described
above. No severe toxicities were observed in the urinary bladder,
kidney or liver. Grade 4 pulmonary toxicity occurred only in one
(1 %) patient, who developed severe hypoxaemia during his first
course of treatment and required mechanical ventilation.
DISCUSSION
As the majority of patients die from advanced NSCLC, there is a
compelling need for more effective treatment that offers a realistic
possibility of improving the survival in these patients. The current
multi-institutional phase II trial of CPT-11 and cisplatin in
combination for advanced NSCLC demonstrates the encouraging
response rate of 52%, confirming the preliminary response rate of
54% obtained in a previous phase I trial in advanced NSCLC
(Masuda et al, 1992b). A response rate of 30-40%, a median
survival time of 6-9 months, and a 1-year survival of approxi-
mately 20% are commonly seen in treatments with cisplatin-based
regimens, usually in combination with etoposide or a vinca
alkaloid (Cellerino et al, 1990; Splinter, 1991; Bunn, 1992).
Therefore, the response rate obtained in this study is in the upper
range of the reported trials in NSCLC among combination
chemotherapy regimens currently in use. As the high response rate
of 52% and the 1-year survival rate of 33% obtained here are
encouraging, this combination holds promise not only as primary
therapy for patients with metastatic disease (stage IV) but also for
patients with more localized disease in the adjuvant or neoadju-
vant (induction) setting in combination with surgery and/or radio-
therapy. In the last two instances a better efficacy of this
combination regimen is expected because improved response rates
to chemotherapy in patients with a lower tumourburden have been
demonstrated in patients with NSCLC (Donnadieu et al, 1991) and
other solid tumours (Hong and Bromer, 1983). Recently, a number
of other new chemotherapeutic agents with substantial activity
against NSCLC, including vinorelbine, paclitaxel, docetaxel and
gemicitabine, have become available (Lilenbaum and Green,
1993). The inclusion ofthese agents in combination chemotherapy
regimens may provide a substantial improvement in the treatment
of this disease. Pirker et al (1995) reported that paclitaxel and
cisplatin combination showed a response rate of 35% in patients
with stage IIIB or IV NSCLC. Langer et al (1995) observed a very
high response rate of 62%, a median survival time of 53 weeks,
and a 1-year survival of 54% with a combination ofpaclitaxel and
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carboplatin in 53 patients with advanced NSCLC. In contrast,
Johnson et al (1996) used the same paclitaxel and carboplatin
combination and obtained a relatively disappointing response rate
of27%, a median survival time of 38 weeks, and a 1-year survival
of 32% in patients with stage IV NSCLC. Prospective randomized
trials that compare these new combination regimens with an
existing cisplatin-containing regimen are necessary to determine
whether or not these new agents will truly improve therapeutic
options for patients with advanced NSCLC.
One of the major arguments against the use of chemotherapy
for NSCLC concerns the considerable toxicity. As expected,
leucopenia and diarrhoea, which are typical toxicities of CPT- 1 I
(Fukuoka et al, 1992), were the major toxicities of this combina-
tion regimen, with the most severe toxicities occurring during
cycle I (Table 3). The marked interpatient variation in the toxici-
ties, which is a well-known feature of CPT-11 (Masuda et al,
1992b; 1993), was also noted in this trial. Two patients died on
days 8 and 15 after experiencing severe leucopenia simultaneously
with severe diarrhoea. These lethal toxicities occurred very rapidly
with unpredictable severity during cycle 1. Patients who could
tolerate cycle 1 without major toxic effects were less likely to
experience severe toxicities in subsequent cycles without dose
adjustments. Despite the dose modification procedure, in which
CPT- I I was withheld if the leucocyte count was < 3000 il-I when
treatment was due, grade 3 or 4 leucopenia more frequently
occurred in this trial than in a previous phase II trial of CPT-11
given as a single agent (46% vs 25%) (Fukuoka et al, 1992),
suggesting at least an additive leucopenic effect in combination
with cisplatin. With the availability of recombinant human
granulocyte colony-stimulating factor (rhG-CSF), it has become
possible to reduce the severity and duration of leucopenia induced
by cytotoxic chemotherapy (Gabrilove et al, 1988). At the time of
the current trial rhG-CSF had already become commercially
available. However, the frequency of severe leucopenia did not
decrease in the current study. This may be in part explained by the
fact that the use of rhG-CSF is allowed in Japan only in patients
who experience leucopenia of grade 3 or worse. Diarrhoea was
another principal dose-limiting toxicity observed with this combi-
nation regimen (Table 4). The recent introduction of the use of
high-dose loperamide by Abigerges et al (1994) has substantially
reduced the previously marked CPT- 11-induced diarrhoea.
However, 19% of patients still suffered from grade 3 or 4 delayed
diarrhoea in this trial. Diarrhoea of grade 3 or 4 occurring coinci-
dentally with grade 4 leucopenia and high fever was especially
life-threatening or lethal, in spite of active supportive care
including vigorous intravenous hydration and intravenous admin-
istration of broad-spectrum antibiotics. Much improvement in the
control of this toxic effect is required to make it more easily to
apply safely to a wide variety of patients. Therefore, further
studies to pursue effective methods of overcoming this late
diarrhoea are necessary.
In conclusion, the combination of CPT-11 and cisplatin is an
effective regimen in advanced NSCLC, with a response rate and
survival time that favourably compare with the results of many
other combination chemotherapy regimens in advanced NSCLC.
As the combination of cisplatin and vindesine is the regimen that
has been reported to prolong survival by 10 weeks when compared
with the best supportive care (Grilli et al, 1993; Souquet et al,
1993; Non-small Cell Lung Cancer Collaborative Group, 1995), it
seems useful to compare the effect of these two combination
chemotherapy regimens. Its final role in the treatment of this
disease will be made clear by a currently on-going prospective
randomized trial comparing CPT-11 alone vs a combination of
CPT-11 and cisplatin vs a combination of cisplatin and vindesine
in treating patients with advanced disease. Another trial comparing
a combination of CPT- 1I and cisplatin vs a combination of
cisplatin and vindesine in advanced non-small cell lung cancer is
also in progress in Japan.
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